Effects of maintenance lithium treatment on serum parathyroid hormone and calcium levels: a retrospective longitudinal naturalistic study

Umberto Albert¹, David De Cori¹, Andrea Aguglia¹, Francesca Barbaro¹, Fabio Lanfranco², Filippo Bogetto¹, Giuseppe Maina³

¹Anxiety and Mood Disorders Unit, Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy; ²Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Torino, Italy; ³Department of Mental Health, San Luigi-Gonzaga Hospital, University of Turin, Orbassano, Italy

Objective: The aim of this retrospective longitudinal naturalistic study was to evaluate the effects of maintenance lithium treatment on parathyroid hormone (PTH) and calcium levels.

Methods: A retrospective longitudinal naturalistic study design was used. Data were collected from the database of a tertiary psychiatric center covering the years 2010–2014. Included were bipolar patients who had never been exposed to lithium and had lithium started, and who had PTH and total and ionized calcium levels available before and during lithium treatment. Paired t-tests were used to analyze changes in PTH and calcium levels. Linear regressions were performed, with mean lithium level and duration of lithium exposure as independent variables and change in PTH levels as dependent variable.

Results: A total 31 patients were included. The mean duration of lithium treatment was 18.6±11.4 months. PTH levels significantly increased during lithium treatment (+13.55±14.20 pg/mL); the rate of hyperparathyroidism was 12.9%. Neither total nor ionized calcium increased from baseline to follow-up; none of our patients developed hypercalcemia. Linear regressions analyses did not show an effect of duration of lithium exposure or mean lithium level on PTH levels.

Conclusion: Lithium-associated stimulation of parathyroid function is more common than assumed to date. Among parameters to be evaluated prior to lithium implementation, calcium and PTH should be added.

Keywords: bipolar disorder, follow-up study, lithium side-effects

Introduction
Lithium is recommended by all treatment guidelines for bipolar disorder (BD) as a first-line maintenance treatment, and recent trial data have definitely established the efficacy of lithium in the prophylaxis of BD.1–10 The clinical benefit of lithium over the long term, however, has to be balanced against the risks that it might confer. The most commonly reported adverse effects associated with long-term lithium treatment are clinical hypothyroidism and reduced urinary concentrating ability.11–13

Less attention has been devoted to alterations in calcium metabolism potentially associated with long-term lithium treatment. In case-control studies, lithium treatment is associated with increased blood calcium (+0.09 mmol/L) and parathyroid hormone (PTH) (+7.32 pg/mL).12 Rates of lithium-associated hyperparathyroidism, however, vary enormously between studies, from 2.7% to 23.2% and up to 47.8% in elderly patients.14–19 Discrepancies depend on definitions of hyperparathyroidism used and different lengths of exposure to lithium in different samples. Rates of subjects with hypercalcemia also vary considerably across different studies. When total serum
calcium was measured, rates of hypercalcemia were comprised between 3.6% (persistent hypercalcemia) and 15.6%; when ionized calcium was measured, rates increased to 25%–42.3%. In a recent case-control, cross-sectional study, we found that PTH and ionized calcium levels were significantly higher in lithium-exposed patients (n=58) than in subjects never exposed to lithium (n=54). Rates of hyperparathyroidism (PTH levels >65 pg/mL) (8.6%) and hypercalcemia (ionized calcium >1.32 mmol/L) (24.1%) were significantly greater in lithium-exposed subjects.

The exact prevalence of lithium-associated alterations in calcium metabolism and the mechanism by which lithium alters serum calcium and PTH levels are to be further determined. Various hypotheses on the underlying mechanism of hyperparathyroidism have been proposed: increased threshold of the calcium-sensing receptor within the parathyroid gland; increase of PTH; decrease of the intracellular calcium uptake; inhibition of action of glycogen synthase kinase 3b; and reduction of PTH gene transcription. Prospective longitudinal studies might add useful information on this topic.

To date, only four studies prospectively assessed serum calcium and/or PTH levels in patients on long-term lithium treatment. Results of these studies are controversial. Aronoff et al evaluated serum calcium levels in 18 patients (14 “manic depressive”, mixed unipolar, and bipolar patients, and four schizoaffective patients) before lithium, 1 week after starting lithium, with a lithium blood level checked at least 5 days after lithium reached the target oral dose. The electronic medical files (for inpatients) and the medical charts (for outpatients) were reviewed for clinical data and for changes in PTH levels after 1 month, and in the Mak et al study, an increase was evident after 1 month from beginning of the treatment, although the difference became statistically significant only after 6 months.

Prospective longitudinal studies seem to suggest that serum PTH levels do rise on lithium treatment, although the studies do diverge concerning calcium measurements: Christiansen et al found an increase in calcium from the first month, while Aronoff et al, Nielsen et al, and Mak et al did not detect any change in serum calcium levels. Longitudinal studies also differ in identifying the time of occurrence of the increase in PTH levels: in the Nielsen et al study, PTH increased within the first week from lithium institution, while Christiansen et al found a significant increase in PTH levels after 1 month, and in the Mak et al study, an increase was evident after 1 month from beginning of the treatment, although the difference became statistically significant only after 6 months.

Finally, when lithium therapy is stopped, both blood calcium and PTH normalize within several months. If hypercalcemia persists after withdrawal of lithium, decisions about surgery follow the same guidelines as those for patients with primary hyperparathyroidism.

Hyperparathyroidism is associated with increased admissions for nonfatal cardiovascular disease, renal failure, renal stones, fractures, hypertension, cancer, and diabetes; the investigation of long-term consequences of lithium on parathyroid function is then relevant for clinical practice.

The aim of the present retrospective longitudinal study was to compare serum PTH and calcium levels in lithium-exposed bipolar patients before and after lithium institution.

**Material and methods**

**Subjects**

A retrospective, longitudinal, naturalistic study design was used. The data were retrieved from the database of the Anxiety and Mood Disorder Unit, Department of Neuroscience of the University of Turin (Italy), examining patients referred between January 2010 and July 2014. Included in the study were patients (in- and outpatients) with a primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders Version 4 (DSM-IV) Bipolar Disorder I or II (made by psychiatrists with the Structured Clinical Interview for DSM-IV-TR Axis I Disorders [SCID-I/P]®). Inclusion criteria were: 1) at least 18 years of age; 2) patients had to have never been exposed to lithium before; 3) and had to have started lithium, with a lithium blood level checked at least 5 days after lithium reached the target oral dose. The electronic medical files (for inpatients) and the medical charts (for outpatients) were reviewed for clinical data and for changes in PTH levels, and serum total and ionized calcium levels; thyroid stimulating hormone (TSH), triiodothyronine (T3)
and thyroxine (T4), creatinine, urea, sodium, and potassium levels were also examined. When possible, magnesium and phosphate levels were also retrieved. A baseline diagnosis of renal failure, serum creatinine value greater than 1.5 mg/dL, use of diuretics or medications known to impair vitamin D metabolism, and/or preexisting disorders of calcium homeostasis were considered exclusion criteria. The Ethics Committee of the San Giovanni Battista University Hospital approved the study design.

Assessments and procedures
All bipolar subjects referred to our unit (inpatients or outpatients) are examined at their first visit with a semistructured interview, with a format that covers the following areas: a) sociodemographic data; b) diagnoses (current and lifetime) provided by clinicians with at least 4 years of postgraduate clinical experience, by means of the SCID-I/P; c) clinical data (such as type of BD, age at onset of first-ever mood episode, and total number of episodes); d) the Young Mania Rating Scale (YMRS), 17-item Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A), and Clinical Global Impression Scale-Severity of Illness. Use of medications at the time of interview is also recorded; moreover, lifetime exposure to mood stabilizers is recorded by means of direct interview, family members’ interview (when available), and medical records review.

A blood draw for routine blood exam is performed at hospital admission for inpatients, as a part of the clinical management routine. For outpatients, patients are scheduled for a blood test within a week from the study visit. At the time when blood is drawn, patients have been fasting for the previous 10 hours. Blood exams include complete blood count, PTH, total and ionized calcium, TSH, T3 and T4, creatinine, urea, sodium and potassium, and lithium serum levels. For the purposes of the present study, we recorded these data as baseline data (before initiation of lithium treatment).

In addition, for most patients who are regularly followed at our unit as outpatients, we monitor PTH, calcium, TSH, creatinine, urea, electrolytes, and plasma lithium levels every 3–6 months (according to International Society for Bipolar Disorders [ISBD] clinical guidelines). For the purposes of the present study, we recorded the last available blood tests taken during follow-up; these data, taken when patients were on a stable maintenance lithium dose, were defined as the end point.

Exposure to lithium was calculated as mean lithium level (mmol/L) in the follow-up period for each patient; all lithium levels recorded in the hospital databases during these retrospective periods were used to compute the mean lithium level. Duration of lithium exposure in months was also computed for each patient.

Statistical analysis
Primary outcome measures were changes in PTH levels, and total and ionized calcium, between baseline (off lithium or before lithium institution) and end of study (end of follow-up on lithium). The secondary outcome measures were changes in TSH, creatinine, urea, sodium, potassium, magnesium and phosphate levels between baseline and follow-up. Paired t-tests were used to analyze changes in primary and secondary outcome variables. Lastly, linear regressions were performed, with mean lithium level and duration of lithium exposure as the main independent variables and change in PTH levels as the dependent variable.

Results
Of approximately 500 charts screened, 34 bipolar patients had lithium instituted for the first time ever and had at least another blood test taken with serum PTH and calcium levels during follow-up; of these, three subjects were excluded because of hyperparathyroidism (PTH >65 pg/mL) at baseline, due in all cases to 25OH-vitamin D levels <20 ng/mL. A total 31 patients constituted our sample. The mean duration of lithium treatment (mean length of follow-up) was 18.6 ± 11.4 months (range 6–48 months). The mean lithium oral dose at end of follow-up was 720.8 ± 227.2 mg/day, and mean plasma lithium level during the follow-up period was 0.66 ± 0.12 mmol/L. Sociodemographic and clinical characteristics of patients included at baseline are reported in Table 1.

Changes in parameters related to calcium metabolism are reported in Table 2. A significant increase was only reported for PTH levels (mean increase of 13.5 ± 14.20 pg/mL). Five (16.1%) patients developed hyperparathyroidism (PTH levels >65 pg/mL) during the follow-up; of these, one had 25OH-vitamin D levels <20 ng/mL, and once vitamin D was supplemented, PTH levels returned within the normal range. The rate of lithium-associated hyperparathyroidism in our sample was then 12.9% (4/31 subjects). Of note, PTH levels increased without a parallel increase in calcium parameters during the 18.6 month follow-up period. No statistically significant changes were found in thyroid and renal function parameters except for an increase, from baseline to follow-up, in TSH levels. The proportion of patients with
neurological disease and treatment downloaded from https://www.dovepress.com/ by 54.70.40.11 on 31-Dec-2018
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Table 1 Sociodemographic and clinical characteristics of the included patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients never exposed to lithium (N=31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actual age (years), mean ± SD</td>
<td>48.4±15.2</td>
</tr>
<tr>
<td>Sex (male), n (%)</td>
<td>12 (38.7)</td>
</tr>
<tr>
<td>Educational level (years), mean ± SD</td>
<td>12.8±4.6</td>
</tr>
<tr>
<td>Marital status, n (%)</td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>17 (54.8)</td>
</tr>
<tr>
<td>Divorced</td>
<td>2 (6.5)</td>
</tr>
<tr>
<td>Never married</td>
<td>11 (35.5)</td>
</tr>
<tr>
<td>Widowed</td>
<td>1 (3.2)</td>
</tr>
<tr>
<td>Currently working, n (%)</td>
<td>17 (54.8)</td>
</tr>
<tr>
<td>Bipolar disorder, n (%)</td>
<td></td>
</tr>
<tr>
<td>Type I</td>
<td>19 (61.3)</td>
</tr>
<tr>
<td>Type II</td>
<td>12 (38.7)</td>
</tr>
<tr>
<td>Age at onset (years), mean ± SD</td>
<td>27.6±8.9</td>
</tr>
<tr>
<td>Total number of episodes, mean ± SD</td>
<td>7.6±5.3</td>
</tr>
<tr>
<td>Duration of illness (years), mean ± SD</td>
<td>21.8±12.5</td>
</tr>
<tr>
<td>Lithium mean dose (mg/day), mean ± SD</td>
<td>720.8±227.2 (300–1200) (min–max)</td>
</tr>
<tr>
<td>Blood lithium levels (mmol/L), mean ± SD</td>
<td>0.66±0.12</td>
</tr>
<tr>
<td>Length of follow-up (months), mean ± SD</td>
<td>18.6±11.4 (6–48)</td>
</tr>
<tr>
<td>BMI, mean ± SD</td>
<td>25.9±5.1</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; max, maximum; min, minimum.

Discussion

Our retrospective longitudinal study confirmed that maintenance lithium treatment is associated with a significant increase in serum PTH levels. The mean increase found in the present study was 13.5 pg/mL during an 18-month follow-up period. Long-term lithium treatment was also associated with hyperparathyroidism: A total 12.9% of bipolar subjects never exposed to this compound before showed, during the follow-up, PTH levels >65 pg/mL. This rate of hyperparathyroidism is even higher than what we described in a previous study. Interestingly, neither total calcium nor ionized calcium levels increased during lithium treatment in our cohort. We have previously described an increase in PTH and ionized calcium levels in a group of 58 patients in continuous lithium treatment, in line with other literature data highlighting an association between hypercalcemia and lithium therapy. Magnesium and phosphate levels also did not change during follow-up.

Our results are in line with those of the previous longitudinal studies performed to date. Serum PTH levels were found to rise during lithium treatment. Concerning calcium levels, the majority of the prospective studies did not detect any change in serum calcium levels, while only Christiansen et al found an increase in calcium. Longitudinal studies, then, do suggest that the effect of lithium on calcium homeostasis is primarily mediated through an increase in PTH levels; the lack of any significant change in the serum calcium level indicates that for any given level of calcium, the PTH concentration is higher during stable lithium therapy. Lithium-associated hyperparathyroidism, then, appears to be independent of calcium levels. In the present study,

Table 2 Serum PTH and calcium levels at first (basal) and last (end point) measurements

<table>
<thead>
<tr>
<th></th>
<th>Baseline (off lithium)</th>
<th>Follow-up (on lithium)</th>
<th>Paired t-test</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=31</td>
<td>48.45±15.83</td>
<td></td>
<td>5.313</td>
</tr>
<tr>
<td>PTH (pg/mL), mean ± SD</td>
<td>34.90±11.63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal range: 15–65 pg/mL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperparathyroidism, n (%)</td>
<td>0 (0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total calcium (mmol/L), mean ± SD</td>
<td>2.32±0.09</td>
<td>2.36±0.08</td>
<td>–</td>
</tr>
<tr>
<td>Normal range: 2.20–2.60 mmol/L</td>
<td></td>
<td></td>
<td>–1.571</td>
</tr>
<tr>
<td>Hypercalcemia, n (%)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>–</td>
</tr>
<tr>
<td>Ionized calcium (mmol/L), mean ± SD</td>
<td>1.13±0.10</td>
<td>1.12±0.07</td>
<td>0.420</td>
</tr>
<tr>
<td>Normal range: 1.10–1.32 mmol/L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypercalcemia, n (%)</td>
<td>1 (3.2)</td>
<td>0 (0)</td>
<td>–</td>
</tr>
<tr>
<td>Magnesium (mmol/L), mean ± SD</td>
<td>0.88±0.17</td>
<td>0.84±0.10</td>
<td>0.954</td>
</tr>
<tr>
<td>Normal range: 0.62–1.06 mmol/L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phosphate (mmol/L), mean ± SD</td>
<td>1.04±0.22</td>
<td>1.01±0.12</td>
<td>0.684</td>
</tr>
</tbody>
</table>

Notes: *Defined as PTH >65 pg/mL. **Defined as total calcium >2.60 mmol/L. †Defined as ionized calcium >1.32 mmol/L.

Abbreviation: PTH, parathyroid hormone.
calcium levels did not change over an 18-month follow-up period and hypercalcemia rates were <5%, consistent with recent studies using relatively stringent (and clinically useful) definitions for clinical hypercalcemia.\textsuperscript{18,38,39} Our study, moreover, adds to previous findings demonstrating that, also, post-lithium phosphate levels do not differ from pre-lithium levels.\textsuperscript{26–28}

It is still unclear whether lithium initiates the disease or uncovers an underlying state of hyperparathyroidism. Putative mediating mechanisms include the induction of parathyroid hyperplasia and/or adenomas;\textsuperscript{15,40} interference with the negative feedback loop for parathyroid hormone secretion, through altering the threshold of calcium-sensing receptors;\textsuperscript{15,41} and inhibition of glycogen synthase kinase 3b.\textsuperscript{42}

Our results clearly show that lithium treatment may affect calcium metabolism, although the proportion of patients with overt hyperparathyroidism is low. What are the implications for clinical practice? Patients who developed lithium-associated hyperparathyroidism, in our cohort, did not show any signs or symptoms, having total and ionized calcium levels within the normal ranges. Normocalcemic primary hyperparathyroidism is a well-documented nosographic entity and is related to reduced bone density.\textsuperscript{43} Lithium treatment for bipolar disorder is usually lifelong; continuously elevated PTH levels, even with normal calcium levels, can thus lead to reduced bone mineral density, osteoporosis and increased fracture risk. Moreover, older patients and patients with comorbid renal disease may be especially vulnerable to developing symptomatic hypercalcemia and hyperparathyroidism requiring treatment.\textsuperscript{44} The consequences in term of reduced mobilization, disability, and health care costs have to be balanced against the cost of PTH measurements.

The question of whether clinicians should avoid lithium in patients with preexisting hypercalcemia/hyperparathyroidism is an important one for future studies to ascertain. It is probably premature to state that this is the case at the current time. In the case of lithium use in patients with renal failure, for example, it is still advisable to continue lithium most of the time, when carefully weighing the pros and cons of this medication.\textsuperscript{45} It is possible that future studies will give us clinically meaningful indications about prescribing lithium in subjects at risk for hypercalcemia/hyperparathyroidism. As clinicians, however, we have to counterbalance the risks associated with the use of a specific drug (eg, lithium) versus benefits of its long-term use and risks associated with its discontinuation. For lithium, there is a clear demonstration that rapid discontinuation of its use is associated with affective relapses.\textsuperscript{11}

This study has several limitations. First of all, there was no control group. Moreover, the size of the sample was small. However, the strength of our study is in the selection of a group of patients never exposed to lithium before, for which we could examine PTH and calcium levels (both total and ionized calcium) at baseline (before lithium institution) and at follow-up (on stable lithium treatment). The relatively long-term follow-up (mean 18.6 months) is another strength of the present study; previous longitudinal studies followed patients for 2 months\textsuperscript{25} or 3 months,\textsuperscript{26} and only Mak et al had a longer follow-up (24 months).\textsuperscript{28} Our results need to be confirmed in greater samples prospectively followed up.

\begin{table}
\centering
\caption{Thyroid and renal function parameters at first (basal) and last (end point) measurements.}
\begin{tabular}{lrrrr}
\hline
\textbf{} & \textbf{Baseline} & \textbf{Follow-up} & \textbf{Paired t-test} \\
\textbf{} & \textbf{(off lithium)} & \textbf{(on lithium)} & \textbf{} & \textbf{} \\
\hline
\textbf{Clinical hypothyroidism, n (%)\textsuperscript{a}} & 1 (3.2) & 4 (12.9) & – & – \\
\textbf{TSH (\textmu U/mL), mean ± SD} & 1.95±1.41 & 2.61±1.50 & –2.040 & 0.050 \\
\hspace{1cm} Normal range: 0.27–4.2 \textmu U/mL & & & & \\
\textbf{Creatinine (mg/dL), mean ± SD} & 0.79±0.16 & 0.82±0.17 & –1.443 & 0.159 \\
\hspace{1cm} Normal range: 0.5–1.5 mg/dL & & & & \\
\textbf{Urea (mg/dL), mean ± SD} & 29.84±8.43 & 27.06±7.9 & 2.002 & 0.054 \\
\hspace{1cm} Normal range: 10–50 mg/dL & & & & \\
\textbf{Sodium (mmol/L), mean ± SD} & 141.3±2.5 & 140.7±2.8 & 0.950 & 0.350 \\
\hspace{1cm} Normal range: 135–145 mmol/L & & & & \\
\textbf{Potassium (mmol/L), mean ± SD} & 4.09±0.31 & 4.18±0.25 & –1.485 & 0.148 \\
\hspace{1cm} Normal range: 3.5–5.0 mmol/L & & & & \\
\textbf{BMI, mean ± SD} & 25.98±5.08 & 25.66±4.93 & 0.779 & 0.442 \\
\textbf{Psoriasis, n (%)\textsuperscript{b}} & 0 (0) & 1 (3.2) & – & – \\
\hline
\end{tabular}
\textbf{Notes:} \textsuperscript{a}Patients with replacement therapy or TSH >4.2 \textmu U/mL and FT3 <2.6 pg/mL. \textsuperscript{b}Clinical diagnosis made by dermatologist.
\textbf{Abbreviations:} BMI, body mass index; FT3, free triiodothyronine; TSH, thyroid stimulating hormone.
What remains to be further determined is a) which patients are more prone to develop lithium-associated alterations in calcium homeostasis and b) whether longer exposures to lithium (years) will end in hypercalcemia and then symptomatic hyperparathyroidism. In our study, we failed to show a relationship between the duration of exposure to lithium or the mean plasma level of lithium and PTH levels. We can conclude, then, that lithium exposes subjects at a higher risk of an increase in PTH levels and overt hyperparathyroidism but that we still don’t know which patients are particularly vulnerable.

Conclusion
In conclusion, our study shows that lithium does raise PTH levels without altering calcium levels. However, despite results of the studies pointing to an association between lithium treatment and hyperparathyroidism, serum calcium monitoring is not included in the most recent National Institute for Health and Care Excellence (NICE) and American Psychiatric Association (APA) guidelines for the management of patients with BD on long-term lithium therapy. Only the ISBD recommends the addition of calcium (but not PTH levels) to the baseline battery of investigations when treatment with lithium is planned. Repeating serum calcium at 6 months and then annually is also recommended. As a consequence, serum calcium and PTH remain poorly monitored in patients on long-term lithium treatment in clinical practice. Lally et al assessed the extent of screening for calcium dysfunction in a cohort of individuals on long term lithium therapy who were monitored by their general practitioners over a 2-year period and found that 14.4% of 333 patients did not have a serum calcium level measured over this period. The measurement of PTH was only performed in a third of patients with a raised calcium level (5.3% was the prevalence of hypercalcemia).

Clinicians should be aware of the efficacy of lithium in the prophylaxis of BD but also of the potential adverse effects associated with long-term lithium use, including hyperparathyroidism. The evaluation of serum PTH and calcium level should be added to baseline blood tests before lithium implementation and during long-term lithium maintenance. Moreover, it seems prudent to avoid lithium therapy in patients with preexisting hypercalcemia, although this remains to be further investigated. Routine screening evaluation of PTH levels has not been considered necessary until after abnormalities in calcium have been documented. However, given the results of our study showing a more frequent finding of elevated PTH levels in comparison with serum calcium concentrations, we speculate that monitoring PTH rather than calcium level in lithium-treated patients should be advised. In fact, inappropriately high serum concentration of PTH sustains excessive renal calcium reabsorption, phosphaturia, and 1,25(OH)₂D synthesis, as well as increased bone resorption.

Disclosure
The authors report no conflicts of interest in this work.

References


